SCHEMBL4833765

SCHEMBL4833765

COc1ccc(S(=O)(=O)Nc2ccc(-c3nc4ncc(Br)c(C)c4[nH]3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 11/20 0.57
CHEK2 O96017 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAPT P10636 1/20 0.49
IKBKE Q14164 7/20 0.49
AURKB Q96GD4 7/20 0.49
CDK2 P24941 5/20 0.49
KIT P10721 2/20 0.48
PLAU P00749 1/20 0.47
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
JAK3 P52333 1/20 0.46
LMNA P02545 2/20 0.46
GAA P10253 1/20 0.46
MAPK1 P28482 1/20 0.46
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6247592 0.90 TBK1 (0.47) TBK1CHEK2SMN1; SMN2MAPTIKBKE
SCHEMBL4842204 0.86 TBK1 (0.44) TBK1MAPTIKBKEAURKBCDK2
SCHEMBL4842115 0.85 TBK1 (0.49) TBK1MAPTIKBKEKIT
SCHEMBL4834658 0.83 JAK1 (0.52) TBK1CHEK2SMN1; SMN2MAPTKIT
SCHEMBL6248698 0.80 SGK1 (0.51) TBK1SMN1; SMN2MAPTLMNAGAA
SCHEMBL4834990 0.79 SGK1 (0.54) TBK1MAPT
SCHEMBL4838253 0.78 TSHR (0.47) TBK1SMN1; SMN2IKBKELMNAMAPK1
SCHEMBL4841855 0.76 MEN1 (0.56) TBK1MAPTGAAHTT
SCHEMBL4843803 0.72 TP53 (0.46) SMN1; SMN2MAPTKITJAK2JAK1
SCHEMBL22223723 0.72 SMN1; SMN2 (0.51) CHEK2SMN1; SMN2MAPTKITPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US claimed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP claimed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US claimed
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 TBK1 1029/4885CHEK2 309/4885SMN1; SMN2 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.